Cdmo Services
Skip to main content

Explore about our broad range of CDMO Services and Products

New MOVE3®: kd-pür® Omega-3 + NEM® Combo Study Confirms Fast Efficacy in Pain & Stiffness Treatment in Healthy Adults

New MOVE3®

BIOGGIO, SWITZERLAND – August 5, 2020 – KD Pharma Group SA and Stratum Nutrition® announce their recent partnership to develop a unique joint health formula combining Stratum's NEM® brand eggshell membrane and KD Pharma's kd-pür® marine omega oils. The combination product is being marketed as MOVE3® and sold in softgels via Stratum and KD's global sales forces. Stratum and KD have agreed on a global exclusive to combine NEM® and kd-pür® marine fish oils. A recent study has been published evaluating the combination's joint pain and stiffness treatment after exercise.

The International Journal of Physical Medicine and Rehabilitation (DOI: 10.35248/2329-9096.20.08.551) recently published a randomized, double-blind, placebo-controlled study designed to evaluate whether the combination of NEM® brand eggshell membrane and kd-pür® brand concentrated omega-3 EPA/DHA from fish oil (MOVE3®) versus placebo would reduce cartilage turnover and alleviate joint pain and/or stiffness immediately following exercise and 12 hours post exercise in 85 healthy men & women (40-75 years) who performed a step exercise regimen (40 to 100 steps per leg) on alternating days for two consecutive weeks.

MOVE3® produced statistically significant reductions in levels of CTX-II, a biomarker of cartilage degradation, versus placebo after 1 and 2 weeks of exercise (-12.9% & -17.7%, respectively). Compared with placebo, MOVE3® supplementation also significantly relieved joint pain immediately after exercise (-28.6%, p=0.049) at 1 week, pain 12 hours after exercise (-46.7%, p=0.035) at 1 week, and stiffness 12 hours after exercise at 1 week (-40%, p= 0.042).  Use of a nutraceutical such as MOVE3® is a promising new approach for alleviating joint pain and stiffness associated with exercise.

"The body of science supporting exercise and recovery benefits for both Omega-3 and NEM continues to grow, but this study is unique because it demonstrates benefits in healthy people consuming the MOVE3 formulation after they have exercised," said Adam Ismail, Chief Strategy Officer of the KD Pharma Group. "For sports nutrition products, it is important that consumers be able to feel the benefit, and the fact that we saw a significant improvement compared to placebo means the subjects not only felt the impact of MOVE3 but observed the effects in a rapid timeframe."

"Conducting this clinical trial in exercising healthy adults will allow brands to make label claims relating to joint pain and stiffness and even cartilage protection," added Kevin Ruff, Ph.D., MBA, Senior Director of Scientific & Regulatory Affairs for Stratum Nutrition.  "This is an additional benefit that MOVE3® provides beyond any other combination product on the market."


About the KD Pharma Group SA
The KD Pharma Group SA is a contract manufacturer that develops products in the pharmaceutical and nutraceutical space. It is also one of the largest Omega-3 fatty acid producers in the world with 500 employees and a presence in the UK, Norway, Germany, Switzerland and the US. The KD Pharma Group employs state-of-the-art technology which is protected by numerous patents. Visit to learn more. 

Adam Ismail
Chief Strategy Officer
KD Pharma Group
+1 (385) 237-2787

About Stratum Nutrition
Stratum is the global leader in eggshell membrane science and technology for joint health with products in over 20 countries. For more information about NEM® and other ingredients, please visit